Jamjoom Pharma and Viatris Sign Local Manufacturing Agreement

Jamjoom Pharma Partners with Viatris for Local Manufacturing

Jamjoom Pharmaceuticals has officially signed a local manufacturing agreement with Viatris Arabia Ltd., a subsidiary of the global healthcare firm Viatris. This collaboration marks a significant step in bolstering local manufacturing capabilities within Saudi Arabia’s healthcare sector.

Enhancing Local Production

Under the new partnership, Jamjoom Pharma will be responsible for the manufacture of various products from Viatris’ extensive portfolio. These products span multiple therapeutic areas and aim to be made readily available to patients across the Kingdom. By localizing production, the agreement presents an opportunity to not only increase access to necessary medications but also to assure their quality in alignment with local standards.

Commitment to Saudi Vision 2030

According to a statement from Jamjoom Pharmaceuticals, this initiative is in direct support of the Saudi Vision 2030, a strategic framework aimed at reducing the country’s dependence on oil and increasing the role of the private sector in the economy. The agreement is seen as a crucial move to enhance local manufacturing capabilities, ultimately aiming to promote sustainable access to high-quality medicines for all patients in Saudi Arabia.

As the healthcare landscape in Saudi Arabia continues to evolve, partnerships like this one between Jamjoom Pharma and Viatris signify a commitment to fostering innovation and self-sufficiency in the pharmaceutical industry, contributing positively to the nation’s economic goals.